Trial results
$SYRE — SPY072
Spyre Therapeutics, Inc. (SYRE) SPY072: trial results in Psoriatic Arthritis (PsA), Axial Spondyloarthritis (axSpA), 2026.
The catalyst
"remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation ("I&I"), with multiple expected topline readouts over the next 12-18 months:"
— Spyre Therapeutics, Inc., 8-K filed 2026-09-08 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
SYRE-SPY072-2026- Company
- Spyre Therapeutics, Inc.
- Kind
- Trial results
- Indication
- Psoriatic Arthritis (PsA), Axial Spondyloarthritis (axSpA)
- Window
- 2026-10-01 – 2026-12-31
- Status
- slate
The bar
No bar has been published for this event yet.
Verdicts
Sealed with the bar. Any verdict for this event reaches this page on 2027-01-30; subscribers get it on the day.